NASDAQ:AVDL Avadel Pharmaceuticals Q1 2025 Earnings Report $8.69 +0.08 (+0.93%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$8.70 +0.01 (+0.06%) As of 05/2/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Avadel Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.06Beat/MissN/AOne Year Ago EPSN/AAvadel Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$50.57 millionBeat/MissN/AYoY Revenue GrowthN/AAvadel Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/7/2025TimeBefore Market OpensConference Call DateWednesday, May 7, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Avadel Pharmaceuticals Earnings HeadlinesAnalysts Set Avadel Pharmaceuticals plc (NASDAQ:AVDL) Price Target at $19.88May 4 at 1:07 AM | americanbankingnews.comAvadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7April 30, 2025 | globenewswire.comElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.May 4, 2025 | Weiss Ratings (Ad)Avadel, nference announce publication of data on sodium oxybateApril 17, 2025 | markets.businessinsider.comAvadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical NeuroscienceApril 17, 2025 | globenewswire.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Could Be Less Than A Year Away From ProfitabilityApril 14, 2025 | finance.yahoo.comSee More Avadel Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avadel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avadel Pharmaceuticals and other key companies, straight to your email. Email Address About Avadel PharmaceuticalsAvadel Pharmaceuticals (NASDAQ:AVDL) operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.View Avadel Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback PlanMicrosoft Crushes Earnings, What’s Next for MSFT Stock?Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay AwayAMD Stock Signals Strong Buy Ahead of Earnings Upcoming Earnings Palantir Technologies (5/5/2025)Vertex Pharmaceuticals (5/5/2025)Realty Income (5/5/2025)Williams Companies (5/5/2025)CRH (5/5/2025)Advanced Micro Devices (5/6/2025)American Electric Power (5/6/2025)Constellation Energy (5/6/2025)Marriott International (5/6/2025)Energy Transfer (5/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
